scholarly journals Corrigendum: Prevalence and clinical characteristics associated with peripheral neuropathy amongst persons on HAART in Busia County, Kenya

2021 ◽  
Vol 77 (1) ◽  
Author(s):  
John N. Mukoma ◽  
Joseph M. Matheri ◽  
Nassib Tawa

No abstract available.

2017 ◽  
Vol 130 (14) ◽  
pp. 1683-1688 ◽  
Author(s):  
Bo Sun ◽  
Li-Zhi Liu ◽  
Yi-Fan Li ◽  
Zhao-Hui Chen ◽  
Li Ling ◽  
...  

2018 ◽  
Vol 128 (05) ◽  
pp. 347-349 ◽  
Author(s):  
Prashanth R.J. Vas ◽  
Nikolaos Papanas

AbstractThe association between diabetes and depression is well recognised. Similarly, diabetic peripheral neuropathy (DPN) is a frequent complication of diabetes. Given the high prevalence of these conditions individually, it is hardly surprising they frequently interact, conferring additional morbidity and a higher mortality risk. Despite this, the specific clinical characteristics that underpin co-morbid depression and DPN remain unclear. Additionally, there is insufficient insight into causal pathways and temporal trends. High-quality epidemiological data is limited, but they suggest that these conditions may share certain common risk factors, although there are also distinct differences such as gender. Improved insights into the risk factors for the co-existence of DPN and depression may help towards improved screening for and treatment of these conditions.


1997 ◽  
Vol 8 (2) ◽  
pp. 187-190 ◽  
Author(s):  
P.H. E. Hilkens ◽  
J. Verweij ◽  
Ch. J. Vecht ◽  
G. Stoter ◽  
M.J. van den Bent

2021 ◽  
Vol 39 (1) ◽  
pp. 1-9
Author(s):  
Kyomin Choi ◽  
Jeeyoung Oh

Peripheral neuropathy and pain are common adverse effects of chemotherapy, which incidence are rising significantly commensurate with extension of survival period in cancer patients. Chemotherapy-induced peripheral neuropathy is caused by most commonly used chemotherapeutic agents including platinum compounds, taxenes, proteasome inhibitors, thalidomide, and vinca alkaloids. Management of neuropathy and pain caused by chemotherapy is still challenging due to there is no proven therapies and preventive methods. The pain and its impact are becoming a main deterioration factor in quality of life and economic burden in our society. We review the mechanism, clinical characteristics, updated evidence of possible management of neuropathy and pain caused by traditional chemotherapeutic agents for contributing to the application of clinicians in their actual medical environment.


Author(s):  
Maria Zafeiri ◽  
Constantinos Tsioutis ◽  
Zoe Kleinaki ◽  
Philip Manolopoulos ◽  
Ioannis Ioannidis ◽  
...  

Abstract Objectives Both diabetic peripheral neuropathy and depression have significant implications on patients’ quality of life, management and outcomes. We aimed to evaluate all available evidence concerning patients with co-existent diabetic peripheral neuropathy and depression, and describe their clinical characteristics, in order to promote early recognition and management. Methods Systematic search of PubMed for studies providing data on patients with diabetic peripheral neuropathy and depression. The primary outcome was to evaluate all available evidence related to characteristics of diabetes, diabetic peripheral neuropathy and depression. Secondary study outcomes included comorbid conditions and complications in these patients. Results Final analysis included 24 studies with data on 205 patients. Most patients were adults between 18–65 years of age. Mean HbA1c value was above 8% and most patients were treated with insulin. Neuropathy was predominantly painful and most patients with available data were considered to have major depressive disorder. In addition to diabetic peripheral neuropathy and depression, diabetes-related complications were recorded in 43 patients, the most common being autonomic neuropathy, retinopathy and nephropathy. The most frequently reported comorbidities were weight loss (72 patients), impotence (60 patients), hypertension (23 patients) and coronary artery disease (22 patients). Conclusions The present study describes the characteristics of patients with co-existent diabetic peripheral neuropathy and depression, aiming for prompt detection, prevention of further deterioration and improvement of patient outcomes. Available evidence shows that the majority of these patients are adults, with painful peripheral neuropathy and with insulin-treated and inadequately controlled diabetes.


2019 ◽  
Vol 38 (8) ◽  
pp. 2099-2107 ◽  
Author(s):  
Yanshan Li ◽  
Li Jiang ◽  
Zhenchun Zhang ◽  
Hong Li ◽  
Liangjun Jiang ◽  
...  

2017 ◽  
Vol 48 (3-4) ◽  
pp. 87-94 ◽  
Author(s):  
Patompong Ungprasert ◽  
Cynthia S. Crowson ◽  
Eric L. Matteson

Background/Aims: Neurosarcoidosis is a rare condition with serious health consequences. However, little is known about clinical characteristics and outcome of neurosarcoidosis in the community setting. Methods: Patients with neurosarcoidosis were identified from a previously described cohort of patients with incident sarcoidosis from Olmsted County, Minnesota, United States from 1976 to 2013 using individual medical record review. Data on clinical characteristics, treatment, and outcome were collected. Results: Neurological involvement by sarcoidosis occurred in 11 patients (3% of all patients with sarcoidosis). Cranial neuropathy was the most common type of neurological disease (5 patients; 45%) followed by peripheral neuropathy (3 patients; 27%), and meningitis (3 patients; 27%). Cerebrospinal fluid (CSF) pleocytosis and elevated CSF protein levels were observed in patients with meningitis, intramedullary spinal cord sarcoidosis, intracranial mass lesion and some patients with cranial neuropathy but were normal in patients with peripheral neuropathy. All patients received high-dose glucocorticoids as initial treatment and almost all responded to this therapy. Relapse after glucocorticoid dose reduction necessitated subsequent treatment with steroid-sparing agents in 4 patients. Conclusion: Neurosarcoidosis is an uncommon manifestation of sarcoidosis. Neurosarcoidosis manifestations generally responded well to high-dose glucocorticoids in the majority of patients, but relapse was common.


Sign in / Sign up

Export Citation Format

Share Document